609 articles
A Phase 1 trial examines how gadobutrol moves through and exits the bodies of newborns and toddlers undergoing routine contrast MRI.
A Phase II pilot trial tests whether adding carfilzomib to plasma exchange and IVIG can safely reverse antibody-mediated rejection after lung transplantation.
Mayo Clinic tests whether 6 months of the SGLT2 inhibitor dapagliflozin can reduce exercise-induced cardiac pressure in preserved-ejection-fraction heart failure.
A Phase 1 trial evaluates DNA and protein HIV vaccines given alone or together to assess safety and immune response in healthy adults.
A Phase 1/2 trial evaluates whether an mRNA-based quadrivalent influenza vaccine can match or beat standard and high-dose comparators in adults.
A completed trial tests whether diode laser treatment reduces TLR-4 in saliva, linking periodontal inflammation to systemic aging biology.
A 12-week trial tested whether a bioactive hydrolysate could reduce gut discomfort, inflammation, and blood sugar issues in healthy elderly participants.
A completed trial examines how a key inflammation pathway connects periodontitis stages to the chronic low-grade inflammation of aging.
Phase 1 trial evaluates PF-06863135 (elranatamab) alone and with immunomodulatory agents to find safe dosing in heavily pretreated myeloma patients.
A sponsored 90-day trial of enhanced-absorption quercetin targeting cholesterol, blood sugar, and metabolic age was terminated before completion.
A UCSF study maps how transfusional iron loading harms the pituitary gland and reproductive hormones in thalassemia patients.
A Phase 2 trial tests a GalNAc-conjugated antisense therapy in familial partial lipodystrophy patients with dangerously high triglycerides.
